Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial

Isabelle Borget (1, 2, 3) , Julia Bonastre (1, 2) , Bogdan Catargi , Désirée Deandreis (4) , Slimane Zerdoud , Daniela Rusu , Stéphane Bardet , Laurence Leenhardt , Delphine Bastié , Claire Schvartz , Pierre Vera (5) , Olivier Morel , Daniele Benisvy , Claire Bournaud , Françoise Bonichon , Antony Kelly , Marie-Elisabeth Toubert , Sophie Leboulleux (4) , Florence Journeau , Ellen Benhamou (2, 1) , Martin Schlumberger (4)

1 U1018 (Équipe 2) - Méthodologie et épidémiologie clinique en oncologie moléculaire
2 SBE - Service de biostatistique et d'épidémiologie
3 UP11 - Université Paris-Sud - Paris 11
4 Médecine nucléaire
5 QuantIF-LITIS - Equipe Quantification en Imagerie Fonctionnelle

In the ESTIMABL phase III trial, the thyroid ablation rate was equivalent for the two thyroid-stimulating hormone (TSH) stimulation methods (thyroid hormone withdrawal [THW] and recombinant human TSH [rhTSH]) and the two iodine-131 ((131)I) activities (1.1 or 3.7 GBq). The objectives of this article were to present health-related quality-of-life (HRQoL) results and a cost-effectiveness evaluation performed alongside this trial.

Domaines: Cancer

Isabelle Borget, Julia Bonastre, Bogdan Catargi, Désirée Deandreis, Slimane Zerdoud, et al.. Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial. Journal of Clinical Oncology, 2015, 33 (26), pp.2885 - 2892. ⟨10.1200/JCO.2015.61.6722⟩. ⟨hal-01648143⟩